Amneal Kashiv Deal: Timeline and Profit & Loss Implications for 2028

Quantifying the timeline and P&L inflection for Kashiv synergies + elimination of partner economics (accretive impact)

Based on Amneal’s Q1’26 earnings call commentary around the Kashiv acquisition, the company frames accretion primarily as a time-based ramp: (i) “day 1” value creation from the deal structure and (ii) synergy/benefit realization that is explicitly tied to 2028 for accretion, with additional operational markers (pipeline approvals in 2027–2029 and manufacturing capacity scaling by 2028).

1) When do the synergies/“full economics” become accretive? (timeline)

A. Accretion timing anchored to 2028

• Management states dilution persists “until it becomes accretive in 2028,” implying the P&L inflection (accretive net effect) occurs by 2028. ¹

B. Financial benefits from the acquisition are “over the course of time” with a multi-year synergy pool

• The company expects $400 million to $500 million in cumulative financial synergies over time, which indicates benefits are not all realized immediately but accumulate across multiple years after close. ²

C. Annual/periodic growth targets suggest benefits show up in the combined run-rate through 2027 and into 2030

• Management’s combined outlook (including Kashiv) points to 2027 and beyond continued top- and bottom-line growth, and by 2030 expects revenues +~$1.2 billion (~40%) vs 2026 and EPS +~$0.70 (~70%) vs 2026. ³
• Separately, for 2027, they explicitly discuss EBITDA guidance (see next section), which is consistent with synergy and economics being sufficient to grow even with transaction dilution (at least at the run-rate level). ¹

D. Operational milestones that likely drive the pace of realized partner-economics capture While not explicitly labeled as “partner-economics accretive,” management links “full economics” capture (i.e., eliminating prior profit-sharing/milestones) to future commercial execution through specific asset and capacity milestones:

• Management says they are capturing full economics from partnered assets by eliminating milestones and profit-sharing obligations from prior licensing deals (this is the direct “eliminated partner economics” mechanism). ²
• They cite partnered asset approvals timing: one expected in Q3 (lanreotide) and another by year-end (biosimilar XOLAIR), followed by additional approvals in 2028 and 2029 (ORENCIA and CIMZIA). ⁴
• They also cite manufacturing capacity scaling from 26,000 liters in 2026 to 75,000 liters by 2028, which provides a capacity ramp that can support increasing revenue contribution as the economics transition to full capture and volumes scale. ⁵

Practical synthesis of the timeline (from the language used)

• 2026: Transaction impacts expected in the near term (management notes “small impact to cash flow related to near-term transaction and integration costs”). ³
• 2027: Benefits are expected to be present enough that adjusted EBITDA guidance targets ~9% growth off 2026’s midpoint, but dilution still appears to affect the “accretive” story (accresive only later). ¹
• By 2028: Company explicitly ties accretion to 2028, which is also the year by which manufacturing capacity reaches 75,000 liters and where you start to see material ramp conditions (approval cadence extends through 2028–2029). ¹⁵⁴
• Beyond 2028 to 2030: Synergy value continues to accumulate toward the stated cumulative pool ($400m–$500m) and larger 2030 revenue/EPS deltas. ²³

---

2) P&L inflection: what quantitative “shape” does management provide?

Because the call excerpts do not provide a year-by-year waterfall directly isolating “partner economics eliminated” vs “synergies,” the best quantification available is to use (i) the stated synergy pool, (ii) the accretion year, and (iii) EBITDA/EPS deltas guided by 2027 and 2030 targets.

A. The accretive P&L inflection year (explicit)

• Accretion occurs in 2028 after an implied dilution in 2027. ¹

B. EBITDA growth framing shows the P&L is not “stalling” during the dilution window

• Management’s 2027 midpoint EBITDA guidance is $820 million. ¹
• They compare this to “Street” around $835 million, and argue that the difference is not substantially less. ¹
• They characterize deceleration as modest: 2026 midpoint EBITDA is $755 million representing about 10% growth, and even at the low end of the 2027 guidance, that’s about 9% growth. ¹
• They attribute confidence to continued growth “even absorbing a strategic deal,” with the explicit caveat that dilution lasts until accretion in 2028. ¹

This means the “P&L inflection” is two-stage:

1. Run-rate profitability continues to grow in 2027 despite transaction effects (EBITDA up ~9–10% type framing). ¹
2. Net accretion flips in 2028 once the deal-related dilution and integration/implementation effects wash out and benefits mature. ¹

C. Synergy dollar magnitude (cumulative) and mechanism (full economics)

• Total expected cumulative financial synergies: $400m–$500m over time. ²
• A key element is explicitly the elimination of milestones and profit-sharing obligations—i.e., converting partnered economics into “full economics” captured by Amneal. ²

D. Larger EPS and revenue inflection by 2030 (combined economics + execution)

• By 2030, management expects revenues +~$1.2 billion (~40%) vs 2026 and EPS +~$0.70 (~70%) vs 2026. ³
• They also frame the 2030 result as coming from a combination of growth of the existing business plus acquisition, and describe the forecast as “highly derisked” and conservative. ⁶

---

3) When does “full economics / eliminated partner economics” plausibly start showing up in P&L?

The excerpt provides mechanism and timing signals, but not a quantified “first year contribution” directly labeled as partner-economics accretive. Still, we can infer the earliest P&L traction points:

• The “full economics” benefit mechanism is already defined as eliminating milestones and profit-sharing obligations on partnered assets. ²
• The company then points to specific partnered asset approvals that occur starting in Q3 (one approval) and year-end (another), plus further approvals in 2028 and 2029. ⁴

Therefore, the likely earliest earnings traction from eliminating partner economics would begin as those partnered assets transition into Amneal’s fully captured value streams—starting with Q3/year-end 2026 approvals described in the call and continuing through 2028–2029 approvals. ⁴
But the company’s consolidated accretion statement remains anchored to 2028, suggesting that even if certain economics are captured earlier, the net combined P&L flips only when the overall integration, cost structure, volume ramps, and cumulative synergies mature. ¹

---

Bottom line (direct answer)

• Accretive P&L timing: Management explicitly says the deal has dilution next year until it becomes accretive in 2028. ¹
• Synergy/“full economics” realization pattern: Management expects $400m–$500m cumulative financial synergies over time, with a key driver being capturing full economics from partnered assets by eliminating milestones and profit-sharing obligations. ²
• Operational anchors supporting the 2028 accretion inflection: manufacturing capacity ramps from 26,000 liters (2026) to 75,000 liters (2028) and partnered-asset approval cadence extends through 2028 and 2029, consistent with benefits becoming more material by 2028 rather than instantly. ⁵⁴
• Quantitative P&L shape around the inflection: in 2027, management guides EBITDA of $820m and describes growth of roughly 9–10% versus 2026’s $755m midpoint, while still stating accretion occurs in 2028—implying the inflection is about net contribution after dilution rather than the absence of growth. ¹

If you want the strictest possible “P&L inflection quantification” isolated specifically to partner economics elimination (not total synergies), the provided excerpts do not disclose a year-by-year split—only the mechanism plus the overall synergy pool and the consolidated accretion year. ²¹